Key Takeaways
- • European healthcare M&A momentum accelerated through 2025 and is entering 2026 with renewed visibility, representing a structurally attractive setup for private equity investors across large-cap and mid-market deals rather than a cyclical uptick.
- • Private equity returns remain a central concern, currently lagging public market benchmarks after two decades of consistent outperformance, prompting allocators to concentrate capital with top-performing firms while reducing exposure to weaker managers.
- • Record dry powder and falling borrowing costs are positioning private equity for continued healthcare M&A activity in 2026, though firms remain burdened by a multi-trillion-dollar backlog of unsold assets acquired during the low-rate era that will take years to liquidate.
- • Secondary sales of private equity stakes are expected to remain elevated in 2026 as large allocators seek liquidity and flexibility, with GP-led secondaries becoming a permanent market feature rather than a temporary release mechanism.
- • 2026 marks an inflection point for private equity discipline, with the industry shifting from the legacy challenges of weak exits and distribution shortfalls toward a gradual recovery driven by an improving IPO market and falling interest rates.
Summary
European healthcare and life sciences M&A is entering 2026 with structural momentum following a robust recovery in 2025. Multiple institutional outlooks indicate that private equity capital is flowing toward predictable revenue streams within healthcare, and the market setup reflects more than cyclical improvement. According to Kearney's assessment and supporting institutional research, healthcare M&A activity momentum is expected to continue, driven by private equity and infrastructure funds actively evaluating opportunities across the sector.
The private equity industry faces a critical juncture as it enters 2026. After a prolonged period of elevated interest rates, subdued deal activity, and limited distributions, market conditions are gradually improving. Falling borrowing costs, a reopening IPO market, and improving sentiment suggest the beginning of a durable recovery. However, this recovery is constrained by structural legacy challenges. Private equity firms are carrying a record backlog of unsold portfolio companies worth trillions of dollars, many acquired during the era of cheap capital and inflated valuations. Even with accelerating deal activity, this inventory will likely require multiple years to clear.
Returns performance remains a central competitive concern within the industry. Private equity's historical advantage—consistent outperformance of public markets over two decades—has reversed, with current returns now lagging public benchmarks. This performance shift is reshaping capital allocation behavior among institutional investors. Experienced allocators are consolidating manager relationships, concentrating commitments with smaller cohorts of top-performing firms while simultaneously reducing or exiting relationships with underperforming managers. This flight-to-quality dynamic will likely intensify throughout 2026.
Liquidity pressures are fundamentally reshaping the private equity market structure. The dramatic slowdown in exits post-2022 has left investors with significantly less cash repatriation than expected. Consequently, secondary sales of private equity stakes are projected to remain elevated in 2026 as large allocators seek liquidity, flexibility, and roster consolidation. Combined with increased GP-led secondary transactions, the sector is transitioning from serving as a temporary release valve into a permanent structural feature of the market. This shift reflects a more actively managed secondary market that redistributes capital among managers with differentiated track records.
Fundraising remains constrained despite early signs of recovery. The combination of return underperformance, elevated dry powder levels among existing investors, and ongoing capital reallocation toward top quartile managers suggests that fundraising will not rebound quickly in 2026. For healthcare-focused strategies, however, the attractive market setup and continued PE capital availability position disciplined investors to execute mid-market and large-cap healthcare transactions throughout the year.
The private equity industry faces a critical juncture as it enters 2026. After a prolonged period of elevated interest rates, subdued deal activity, and limited distributions, market conditions are gradually improving. Falling borrowing costs, a reopening IPO market, and improving sentiment suggest the beginning of a durable recovery. However, this recovery is constrained by structural legacy challenges. Private equity firms are carrying a record backlog of unsold portfolio companies worth trillions of dollars, many acquired during the era of cheap capital and inflated valuations. Even with accelerating deal activity, this inventory will likely require multiple years to clear.
Returns performance remains a central competitive concern within the industry. Private equity's historical advantage—consistent outperformance of public markets over two decades—has reversed, with current returns now lagging public benchmarks. This performance shift is reshaping capital allocation behavior among institutional investors. Experienced allocators are consolidating manager relationships, concentrating commitments with smaller cohorts of top-performing firms while simultaneously reducing or exiting relationships with underperforming managers. This flight-to-quality dynamic will likely intensify throughout 2026.
Liquidity pressures are fundamentally reshaping the private equity market structure. The dramatic slowdown in exits post-2022 has left investors with significantly less cash repatriation than expected. Consequently, secondary sales of private equity stakes are projected to remain elevated in 2026 as large allocators seek liquidity, flexibility, and roster consolidation. Combined with increased GP-led secondary transactions, the sector is transitioning from serving as a temporary release valve into a permanent structural feature of the market. This shift reflects a more actively managed secondary market that redistributes capital among managers with differentiated track records.
Fundraising remains constrained despite early signs of recovery. The combination of return underperformance, elevated dry powder levels among existing investors, and ongoing capital reallocation toward top quartile managers suggests that fundraising will not rebound quickly in 2026. For healthcare-focused strategies, however, the attractive market setup and continued PE capital availability position disciplined investors to execute mid-market and large-cap healthcare transactions throughout the year.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.